Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Am J Reprod Immunol. 2022 Jun;87(6):e13533. doi: 10.1111/aji.13533. Epub 2022 Apr 18.
The pathogenesis of endometriosis remains unclear. Endometrial cells in retrograde menstruation are considered the source of endometriosis; therefore, we hypothesized that the eutopic endometrium may provide clues regarding the pathogenesis. We aimed to clarify the role of eutopic endometrial cells in endometriosis development.
Eutopic endometrial tissues were obtained from patients with or without endometriosis, and expression of cell surface molecules in eutopic endometrial stromal cells (ESCs) was evaluated via iTRAQ-based proteomic analysis. Based on the results, we focused on galectin-3. Galectin-3 expression in clinical samples was confirmed by immunohistochemistry and Western blot analysis. The concentration of secreted galectin-3 was measured using enzyme-linked immunosorbent assays. Adhesion and migration of ESCs were evaluated by in vitro adhesion and wound healing assays. The cytotoxicity of natural killer cells was measured via calcein release assays. Cell proliferation was measured using the CyQUANT Cell Proliferation Assay Kit.
iTRAQ analysis revealed that galectin-3 expression was specifically elevated in the ESCs from endometriosis patients. Immunohistochemistry confirmed galectin-3 overexpression in the eutopic endometrium of endometriosis, irrespective of the menstrual phase. Galectin-3 was overexpressed and secreted by the eutopic ESCs from patients with endometriosis compared to that from patients without endometriosis. Galectin-3 expression in ESCs increased adhesion and migration, whereas galectin-3 inhibitors impaired these processes. Galectin-3 reduced the cytotoxicity of natural killer cells toward ESCs, while not affecting cell proliferation.
Galectin-3 promotes peritoneal engraftment of ESCs due to impaired immune surveillance in the peritoneal cavity and increases ESCs adhesion and migration to the peritoneum.
子宫内膜异位症的发病机制仍不清楚。逆行月经中的子宫内膜细胞被认为是子宫内膜异位症的来源;因此,我们假设在位内膜可能为发病机制提供线索。我们旨在阐明在位内膜细胞在子宫内膜异位症发展中的作用。
从有或没有子宫内膜异位症的患者中获取在位子宫内膜组织,并通过 iTRAQ 基于蛋白质组学分析评估在位子宫内膜基质细胞 (ESCs) 表面分子的表达。基于这些结果,我们重点研究了半乳糖凝集素-3。通过免疫组织化学和 Western blot 分析证实了临床样本中半乳糖凝集素-3的表达。使用酶联免疫吸附试验测量分泌的半乳糖凝集素-3的浓度。通过体外粘附和划痕愈合试验评估 ESC 的粘附和迁移。通过钙黄绿素释放试验测量自然杀伤细胞的细胞毒性。使用 CyQUANT 细胞增殖测定试剂盒测量细胞增殖。
iTRAQ 分析显示,半乳糖凝集素-3在子宫内膜异位症患者的 ESCs 中特异性升高。免疫组织化学证实了子宫内膜异位症在位内膜中半乳糖凝集素-3的过度表达,与月经周期无关。与没有子宫内膜异位症的患者相比,子宫内膜异位症患者的 ESCs 中半乳糖凝集素-3过度表达并分泌。ESCs 中的半乳糖凝集素-3表达增加了粘附和迁移,而半乳糖凝集素-3抑制剂则削弱了这些过程。半乳糖凝集素-3降低了自然杀伤细胞对 ESCs 的细胞毒性,而不影响细胞增殖。
半乳糖凝集素-3通过削弱腹腔内的免疫监视,促进 ESCs 在腹膜中的植入,并增加 ESCs 向腹膜的粘附和迁移。